[Federal Register Volume 75, Number 192 (Tuesday, October 5, 2010)]
[Notices]
[Pages 61501-61502]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-24903]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0496]
Cooperative Agreement To Support Capacity Building Activities
Through the World Health Organization Global Foodborne Infections
Network
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing its
intention to accept and consider a single source application to award a
cooperative agreement to the World Health Organization (WHO) Advisory
Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR)
and in support of the WHO Global Foodborne Infections Network (GFN) and
to provide guidance to the WHO on a framework for the development of an
international network to promote and enhance collaboration on
harmonization and data sharing among countries with Antimicrobial
Resistance (AMR) surveillance programs.
FOR FURTHER INFORMATION AND ADDITIONAL REQUIREMENTS CONTACT:
Program Contact: Patrick McDermott, Division of Animal and Food
Microbiology, Center for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl., Mod II, rm. 1505, Rockville, MD
20855, 301-210-4213, FAX: 301-210-4685, email:
Patrick.McDermott@fda.hhs.gov.
Management Contact: Katherine C. Bond, Office of International
Programs, Office of the Commissioner, FDA, White Oak Bldg. 32, rm.
3300, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-8318,
FAX: 301-595-5058, email: Katherine.Bond@fda.hhs.gov.
Grants Contact: Kimberly Pendleton, Division of Acquisition and
Grants, FDA, 5630 Fishers Lane (HFA-500), rm. 2104, Rockville, MD
20857, 301-827-9363, FAX: 301-827-7101, email:
kimberly.pendleton@fda.hhs.gov.
For more information on this funding opportunity announcement (FOA)
and to obtain detailed requirements, please contact Kimberly Pendleton.
SUPPLEMENTARY INFORMATION:
I. Funding Opportunity Description
[RFA-FD-10-006]
[Catalog of Federal Domestic Assistance Number(s): 93.103 https://www.cfda.gov]
A. Background
The Food and Drug Administration (FDA) is announcing its intention
to accept and consider a single source application for a cooperative
agreement to the WHO GFN. This project represents a collaborative
agreement between the WHO and FDA aimed at capacity building in
laboratory based surveillance of foodborne pathogens and disease in
developing regions to support AGISAR and GFN to enable FDA to realize
its goal of developing an international database for human and animal
isolates of foodborne pathogens and their susceptibility profiles.
B. Research Objectives
Support WHO capacity building activities with member
countries for AMR monitoring (development of AMR training modules for
GFN training courses, and hosting of visiting scientist from developing
countries).
Develop harmonized schemes for monitoring antimicrobial
resistance in zoonotic and enteric bacteria to include appropriate
sampling.
Promote information sharing on AMR (development of a
global AMR databank).
Provide expert advice to WHO, and promote WHO and FDA
collaborative work to advise WHO Member States on containment of AMR
with a particular focus to Human Critically Important Antimicrobials.
AGISAR should be the core advisory group to review criteria for ranking
human and animal antimicrobials to be reviewed by WHO; and FDA's
resources could be used in support of AGISAR's participation.
Support and advise WHO on selection of sentinel sites to
be strategically identified around the globe and designing pilot
projects to conduct integrated surveillance of antimicrobial
resistance.
Promote development of standardized methods for monitoring
antimicrobial use and work with member states for the implementation of
these methods at the country-level.
Promote the development of published articles on the
emergence of AMR threats and challenges, and the
[[Page 61502]]
need for AMR surveillance with a forward-look toward sustainable
solutions through global collaboration and evidence-based approaches.
C. Eligibility Information
The following organizations/institutions are eligible to apply: The
World Health Organization
II. Award Information/Funds Available
A. Award Amount
FDA anticipates providing one award of $847,500 (total costs
including indirect costs) in fiscal year (FY) 2010 in support of this
project. Subject to the availability of funds and successful
performance, 2 additional years of support up to $565,000 per year will
be available.
B. Length of Support
The support will be 1 year with the possibility of an additional 2
years of noncompetitive support. Continuation beyond the first year
will be based on satisfactory performance during the preceding year,
receipt of a non-competing continuation application and available
Federal FY appropriations.
Dated: September 29, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-24903 Filed 10-4-10; 8:45 am]
BILLING CODE 4160-01-S